> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Since Our Last Issue ...
- URL: https://www.fdaweb.com/since-our-last-issue-36/
- Published: 2021-02-15T12:00:00.000Z
- Updated: 2026-09-14T16:46:43.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5137272

**Catalent Pharma Solutions** has broken ground on a $34 million extension to its Madison, WI biologics manufacturing facility. When completed, the additional 22,000 square feet of space will accommodate two 2,000 liter single-use bioreactor systems, allowing the company to support late-phase clinical and commercial production of up to 4,000 liter batches. The new footprint will also support expansion of analytical and process development laboratories, as well as additional office space.

**Verastem**, Inc. and **Infinity Pharmaceuticals** have entered into a license agreement under which Verastem licensed exclusive worldwide rights to develop and commercialize Infinity’s oncology product candidate duvelisib, an oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma for treating hematologic cancers. Under the agreement, Verastem will pay Infinity up to $28 million in milestone payments.

**Fresenius** has acquired lung- and cardiac-focused medtech company **Xenios** from German venture capital group **Zukunftsfonds Heilbronn** for an undisclosed amount. Xenios was formed in 2013 after **Novalung** and **Medos Medizintec**hnik were acquired by the group. Xenios develops and produces systems for lung and cardiac assistance, and employs more than 260 employees.

**Boston Scientific** has acquired the LumenR Tissue Retractor System from **LumenR LLC**, a privately held Newark, CA-based company. The device is currently in development for use during endoscopic resection of lesions in the colon, esophagus or stomach. It is designed to improve endoscopic sub-mucosal dissection and endoscopic mucosal resection procedures which are less invasive alternatives to conventional surgery for the removal of precancerous lesions and malignant tumors in the gastrointestinal tract.